Molecular Cell: CRISPR technology brings revolutionary changes to antibody diagnostic experiments

This important achievement in a CRISPR-based peptide library display and programmable microarray self-assembly for rapid quantitative protein binding assays for the title published in Molecular Cell magazine

Researchers use this platform to detect the binding of antibodies to proteins from pathogens, including SARS-CoV-2 in the blood of COVID-19 patients

The author pointed out that CRISPR-Cas9 technology has been applied to a series of applications for precise genome editing and transcriptional regulation, which allows scientists to effectively manipulate gene sequences at will

The PICASSO technology developed by Barber and colleagues uses an improved Cas9 enzyme to facilitate the research of custom peptide libraries, overcoming the limitations of current display technologies

"During the development of PICASSO, we demonstrated the use of a CRISPR-based system for self-assembly of peptide libraries, allowing rapid custom protein research to use common molecular biology reagents in any laboratory

These dCas9 peptides are fused and self-assembled to a position on the surface of a DNA microarray, complementary to their sgRNA barcodes

The team pointed out: "A single mixing pool of dCas9 fusion peptides can be positioned to a user-programmed position on the microarray surface, which contains DNA sequences complementary to the sgRNA barcode of each peptide

When describing this technique, Barber said: "Imagine you want to paint on a canvas, but instead of using a normal way, you mix all the paint together and splash it on the canvas, and the perfect picture will appear.

Barber commented: "In this work, we demonstrated the application of PICASSO in protein research and created a tool that we believe can be quickly applied to medical diagnosis

Elledge commented: “One of the most exciting aspects of this work is to show how CRISPR can be applied to a whole new environment

(Biocom)

Original link:

https://doi.